Castle BiosciencesCSTL -1.52%77 Receivables Turnover is 1.95 as of Mar. 2026. GuruFocus rates CSTL with a GF Score™ of 77/100 and a GF Value™ of $29.19 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Castle Biosciences ranks better than 66.01% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Castle Biosciences's Revenue for the
three
months ended in Mar. 2026 was $83.7 Mil. Castle Biosciences's average Accounts Receivable for the
three
months ended in Mar. 2026 was $42.8 Mil.
Hence, Castle Biosciences's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.95.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Castle Biosciences Receivables Turnover Related Terms
Castle Biosciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Castle Biosciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSTL vs FLGT, MYGN, OPK: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Castle Biosciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (CSTL) has a Receivables Turnover of 1.95 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Castle Biosciences and its competitors. According to the industry distribution chart, Castle Biosciences ranks #69 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 34%.
Is Castle Biosciences' Receivables Turnover too high?
Castle Biosciences' current Receivables Turnover is 1.95. The Medical Diagnostics & Research industry median Receivables Turnover is 5.39. Castle Biosciences' value of 1.95 is 63.8% below this industry median. Based on the distribution chart, Castle Biosciences ranks #69 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Castle Biosciences has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Receivables Turnover compare to FLGT and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #69 out of 203 companies for Receivables Turnover. This puts Castle Biosciences in the upper half of its industry. The industry median Receivables Turnover is 5.39. Castle Biosciences' value of 1.95 is 63.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.39, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Castle Biosciences's current Receivables Turnover of 1.95 is 63.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Castle Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Castle Biosciences's current Receivables Turnover is 1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.19, compared to a current price of $23.47 — trading 19.6% below its estimated fair value. The current Receivables Turnover is 1.95 and 63.8% below the Medical Diagnostics & Research industry median of 5.39. Castle Biosciences' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Receivables Turnover is 1.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued.
The current stock price of $23.47 is trading 19.6% below its estimated GF Value™ of $29.19.
GuruFocus considers Castle Biosciences to be Modestly Undervalued.
Key valuation signals for CSTL:
Receivables Turnover: 1.95
GF Value™: $29.19 vs. price of $23.47 (19.6% below fair value)
Industry Position: 63.8% below the Medical Diagnostics & Research median (#69 of 203)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
77GF Score
Get the complete analysis for CSTL
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
